Component

Human DPN-trial HbA1c and lipid measurements

Human DPN-trial HbA1c and lipid measurements

1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. The 2024 neuropathy benefit did not coincide with significant HbA1c, total-cholesterol or triglyceride changes.

    Experimental context and source evidence
    evidence_access
    Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.
    experimental_contrast
    {"intervention": "ALCAR hydrochloride for 24 weeks", "comparator": "Placebo", "endpoint": "The 2024 neuropathy benefit did not coincide with significant HbA1c, total-cholesterol or triglyceride changes.", "effect_direction": "no_detected_change", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
    experimental_model
    Same randomized trial; supplementary Table 5 described in Results.
    interpretation_status
    Source-derived curation with stated access limits; ungraded, not independent replication.
    limitations
    Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.
    nutrient_topic
    Acetyl-L-carnitine collection; exact intervention and molecular form govern interpretation. · Acetyl-L-carnitine
    plain_language
    The 2024 neuropathy benefit did not coincide with significant HbA1c, total-cholesterol or triglyceride changes.
    primary_references
    Acetyllevocarnitine Hydrochloride for the Treatment of Diabetic Peripheral Neuropathy: A Phase 3 Randomized Clinical Trial in China. | https://pubmed.ncbi.nlm.nih.gov/38320260/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC11043058/ | https://doi.org/10.2337/db23-0377
    source_locator
    Reviewed reference dpn24-metabolic-null; This limits a claim that the composite benefit was demonstrated to result from improved systemic glycemic control.

    Acetyl-L-carnitine: detailed mechanisms of action (reviewed 6 October 2026) · lines 531–537

    AI-assisted original review of primary studies and clearly identified official records. Exact primary access is stated; no independent replication is claimed. · supports · Same randomized trial; supplementary Table 5 described in Results. · Recorded from source · Recorded from source

    ### dpn24-metabolic-null The 2024 neuropathy benefit did not coincide with significant HbA1c, total-cholesterol or triglyceride changes. This limits a claim that the composite benefit was demonstrated to result from improved systemic glycemic control. Model and exposure: Same randomized trial; supplementary Table 5 described in Results. Limitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation. Reference: Acetyllevocarnitine Hydrochloride for the Treatment of Diabetic Peripheral Neuropathy: A Phase 3 Randomized Clinical Trial in China. | 2024 | https://pubmed.ncbi.nlm.nih.gov/38320260/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC11043058/ | https://doi.org/10.2337/db23-0377 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.